Oral GLP-1 Agonists: The Future of Weight Loss and Diabetes Treatment

Eli Lilly's investigational oral daily nonpeptide GLP-1 agonist, Orforglipron, appears comparable with other injectable and oral agents in the class for treating obesity and type 2 diabetes, according to two new phase 2 studies. Orforglipron is a small molecule that isn't a peptide, so it isn't degraded in the gastrointestinal tract, making it more convenient for patients to take. The drug showed promising results in reducing body weight and A1c levels in patients with obesity and type 2 diabetes, respectively, and could potentially improve access to care for people with obesity who don't have the means to afford effective treatments.